Who is sponsoring NCT03912480?

NCT03912480 is sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd..

What drugs are being tested in NCT03912480?

Interventions in NCT03912480: Stem cells from human exfoliated teeth.

What condition does NCT03912480 study?

NCT03912480 studies Type1diabetes.

Is NCT03912480 still recruiting?

NCT03912480 is currently status unknown. Last updated 22 April 2019.

Last reviewed 2019-04-22 · How we verify

NCT03912480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Status unknown EARLY_PHASE1 Last updated 22 April 2019

What this trial tests

EARLY_PHASE1 trial testing Stem cells from human exfoliated teeth in Type1diabetes in 24 participants. Status unknown.

Timeline

5 January 2019

Primary endpoint
30 December 2020

31 March 2021

Quick facts

Lead sponsor	CAR-T (Shanghai) Biotechnology Co., Ltd.
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	5 January 2019
Primary completion	30 December 2020
Estimated completion	31 March 2021
Sites	1 location across China

Drugs / interventions tested

Stem cells from human exfoliated teeth — full drug profile →

Conditions studied

Type1diabetes — all drugs for Type1diabetes →

Sponsor

CAR-T (Shanghai) Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 25 to 70, any sex, with Type1diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of Stem cells from human exfoliated teeth transplantation in patients with Islet function decreased significantly to provides scientific basis for further clinical studies to verify the safety and efficacy. On the basis of maintaining the original treatment, intravenous drip of dental pulp mesenchymal stem cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications.
Li P, Ou Q, Shi S, Shao C. · · 2023 · cited 157× · PMID 36973490 · DOI 10.1038/s41423-023-00998-y
Stem Cell-Based Clinical Trials for Diabetes Mellitus.
de Klerk E, Hebrok M. · · 2021 · cited 78× · PMID 33716982 · DOI 10.3389/fendo.2021.631463
Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges.
Silva IBB, Kimura CH, Colantoni VP, Sogayar MC. · · 2022 · cited 53× · PMID 35840987 · DOI 10.1186/s13287-022-02977-y
Promising advances in clinical trials of dental tissue-derived cell-based regenerative medicine.
Yamada Y, Nakamura-Yamada S, Konoki R, Baba S. · · 2020 · cited 48× · PMID 32398041 · DOI 10.1186/s13287-020-01683-x
Clinical trials using dental stem cells: 2022 update.
Song WP, Jin LY, Zhu MD, Wang H, et al · · 2023 · cited 25× · PMID 37007456 · DOI 10.4252/wjsc.v15.i3.31
Current advancements in cellular immunotherapy for autoimmune disease.
Berry CT, Frazee CS, Herman PJ, Chen S, et al · · 2025 · cited 15× · PMID 39821376 · DOI 10.1007/s00281-024-01034-5
Sinking Our Teeth in Getting Dental Stem Cells to Clinics for Bone Regeneration.
Shoushrah SH, Transfeld JL, Tonk CH, Büchner D, et al · · 2021 · cited 12× · PMID 34203719 · DOI 10.3390/ijms22126387
Research progress on optimization of <i>in vitro</i> isolation, cultivation and preservation methods of dental pulp stem cells for clinical application.
Wang X, Li F, Wu S, Xing W, et al · · 2024 · cited 6× · PMID 38633667 · DOI 10.3389/fbioe.2024.1305614

Verify or expand the search:

Other recruiting trials for Type1diabetes

Currently open trials in the same condition.

NCT07139808 — Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System · NA · recruiting
NCT07092761 — Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System · NA · recruiting
NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
NCT05668507 — REACHOUT Mental Health Support Mobile App · NA · active not recruiting

Other CAR-T (Shanghai) Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT05127369 — Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression · NA · unknown
NCT04302519 — Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells · EARLY_PHASE1 · unknown
NCT04130100 — Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis · EARLY_PHASE1 · unknown
NCT03658655 — Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03912480 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CAR-T (Shanghai) Biotechnology Co., Ltd.
Last refreshed: 22 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing